- Home
- IMPP vs UNCY Comparison
IMPP vs UNCY Comparison
Compare IMPP & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMPP | UNCY |
|---|---|---|
| Founded | 1981 | 2016 |
| Country | Greece | United States |
| Employees | 49 | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.1M | 145.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | IMPP | UNCY |
|---|---|---|
| Price | $4.30 | $6.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | ★ 580.7K | 461.4K |
| Earning Date | 05-22-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | $51.79 | N/A |
| Revenue Next Year | $6.97 | $407.73 |
| P/E Ratio | $3.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.28 | $0.47 |
| 52 Week High | $6.57 | $7.57 |
Technical Indicators
Market Signals| Indicator | IMPP | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 49.11 | 46.47 |
| Support Level | $4.28 | $5.95 |
| Resistance Level | $4.84 | $7.04 |
| Average True Range (ATR) | 0.24 | 0.41 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 43.65 | 30.82 |
Price Performance
Historical ComparisonAbout IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.